Gilead Buys Shortcut For FDA Drug Review For $125 Million
Thursday, November 20, 2014
How much is a fast track for the Food and Drug Administration review of a new drug worth? Try $125 million.
In an auction, Gilead Sciences, a maker of HIV and hepatitis medicines, just bought a coupon good for the accelerated review of a drug of the company’s choice from Knight Therapeutics, a Canadian company.
The priority review voucher entitles Gilead to move a drug of its choice through the FDA four months faster than the normal track.
Source: NPR (link opens in a new window)
- Health Care